313 results about "Inflammatory cell infiltration" patented technology

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention belongs to the field of microorganisms. The invention provides an application of a probiotic composition in preparation of medicines for preventing and treating ulcerative colitis, the probiotic composition comprises a combination of bacillus coagulans and clostridium butyricum, and the combination of bacillus coagulans and clostridium butyricum comprises a combination of bacillus coagulans and clostridium butyricum. The bacillus coagulans is bacillus coagulans JSSW-LA-07-1 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10182, and the clostridium butyricum is clostridium butyricum JSIM-MCB20040312 with the preservation number of CGMCC No.1647. The bacillus coagulans and the clostridium butyricum are used for preparing the bacillus coagulans and the clostridium butyricum. The probiotic composition has the capacity of preventing and treating ulcerative colitis, the ulcerative colitis treating effect is better than that of positive control medicine salazosulfapyridine, the obvious ulcerative colitis treating effect is achieved, the inflammatory factor content and the oxidative stress level are remarkably reduced, inflammatory cell infiltration is reduced, intestinal flora imbalance is improved, and the effect of preventing and treating ulcerative colitis is achieved. Meanwhile, the effect of promoting planting of probiotics is achieved.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention belongs to the technical field of medicines, and discloses application of baicalein in drugs related to the treatment effect of S protein and LPS induced acute lung injury. Specifically, the invention discloses an application of baicalein in preparation of drugs playing a protective role in treating pulmonary edema, inflammatory cell infiltration and cytokine storm caused by acute lung injury induced by S protein combined with LPS. Pharmacological experiments prove that baicalein has an anti-inflammatory effect in treatment of acute lung injury induced by S protein combined with LPS, and can improve pulmonary edema and promote lesion lung tissue repair.

The invention discloses a five-membered heterocyclic compound as well as a preparation method, an intermediate, a composition and application thereof. Specifically provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound provided by the invention has excellent biological activity; on one hand, free radicals can be removed, so that activation of tyrosinase is reduced; on the other hand, the activity of activated tyrosinase can be inhibited, and generation of melanin is reduced from multiple aspects; besides, the compound can reduce skin pigmentation induced by ultraviolet (UVB), has no obvious stimulation and inflammatory cell infiltration during administration, is safe and good in tolerance, has better solubility and preparation performance, is good in skin feeling, and is expected to be widely applied in the industries of medicine, cosmetics and beauty. # imgabs0 #

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses a drug-loaded nanogel modified bioprosthetic valve as well as a preparation method and application thereof, and belongs to the technical field of preparation of medical materials and medical instruments. The preparation method comprises the following steps: firstly, synthesizing an active oxygen response monomer by taking thioketal-containing methacrylate and methylprednisone hemisuccinate as raw materials, then synthesizing active oxygen response type drug-loaded nanogel, and then introducing the active oxygen response type drug-loaded nanogel to the surface of the bioprosthetic valve through chemical bonding; in a pathological environment with relatively high active oxygen concentration, a thioketal group in the monomer is decomposed, and methylprednisone hemisuccinate is released at a fixed point, so that inflammatory cell infiltration is reduced, and the anti-inflammatory performance of the bioprosthetic valve is improved; in addition, the nanogel contains a large number of hydrophilic groups, a hydration layer is formed on the surface of the bioprosthetic valve, and the risk of thrombus and blood coagulation can be effectively reduced; the prepared bioprosthetic valve has excellent anti-inflammatory, anti-coagulation and anti-calcification capabilities and stability.

The present application relates to; a pharmaceutical composition, a food composition and a feed composition for preventing or treating fatty liver diseases; and a method for treating fatty liver diseases by using same, the pharmaceutical composition comprising a Bifidobacterium pseudolongum strain deposited under accession number KCTC 15133BP, a culture of the strain, a lysate of the strain, an extract of the strain, or a mixture thereof. The Bifidobacterium pseudolongum strain deposited under accession number KCTC 15133BP, a culture of the strain, a lysate of the strain, an extract of the strain, or a mixture thereof, according to the present invention, alleviates inflammatory cell infiltration and fibrosis in the liver, and exhibits the effects of inhibiting cholesterol synthesis and inhibiting triglyceride accumulation in the liver, and thus can be used for treating fatty liver diseases, particularly nonalcoholic fatty liver disease.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

The invention discloses an application of a pyroptosis inhibitor in preparation of a product for treating biliary atresia, the pyroptosis inhibitor 2-bromohexadecanoic acid has a certain treatment effect on biliary atresia mice, can significantly prolong the survival time of the mice, improve jaundice, improve the liver function of the mice, reduce the infiltration quantity of inflammatory cells around intrahepatic bile ducts, and can be used for treating the biliary atresia. A new potential target and a treatment strategy are provided for treatment of biliary atresia.

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention discloses an application of bilobalide in preparation of an organ protection solution. According to the application, a mouse liver ischemia reperfusion injury model is adopted; the bilobalide can obviously relieve a plurality of indexes such as liver cell injury caused by liver ischemia reperfusion, pathological injury of a liver tissue structure, liver cell apoptosis, liver inflammatory cell infiltration (neutrophil and macrophage), inflammatory factor expression (secretion of inflammatory cytokines (TNF-alpha and IL-1beta) and the like, and has an obvious protective effect on the liver ischemia reperfusion injury. Research is carried out by combining rat orthotopic liver transplantation with a low-temperature mechanical perfusion model, and experimental research finds that after the liver perfusion preserving fluid containing bilobalide is used for perfusing an in-vitro liver by using a low-temperature mechanical perfusion instrument, the liver function after transplantation can be remarkably protected, and liver injury is reduced.

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.

The invention discloses an application of a meroterpenoid compound I in preparation of an anti-heart failure medicine. The meroterpenoid I separated and purified from marine fungi Aspergillus terreus GZU-311 is used for treating a mouse heart failure model induced by adriamycin or coronary artery left anterior descending branch ligation, and it is found that the meroterpenoid I can improve the heart function of a mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening and improve myocardial cell arrangement disorder, and the meroterpenoid I can be used for treating the heart failure of the mouse induced by adriamycin or coronary artery left anterior descending branch ligation, so that the meroterpenoid I can be used for treating the heart failure of the mouse induced by adriamycin or coronary artery left anterior descending branch ligation. Inflammatory cell infiltration is reduced, and the effect of resisting heart failure is achieved. Therefore, the invention provides the application of the meroterpenoid I in preparing the heart failure resisting medicine. According to the invention, medicine source molecules for treating heart failure are enriched, and development and clinical treatment of anti-heart-failure medicines are facilitated.

The invention discloses a medicine composition for treating atopic dermatitis, a preparation method and application, the medicine composition comprises inactivated malassezia sphaeroides, and the strain preservation number of the malassezia sphaeroides is ATCC 96807. The cream composition disclosed by the invention is externally applied to local treatment of skin lesions of specific dermatitis, supplements skin symbiotic bacteria, assists in recovering skin barriers of patients, remarkably inhibits growth and proliferation of staphylococcus aureus at the skin lesions of dermatitis and exocrine toxins, remarkably relieves inflammatory response, reduces the thickness of cuticles and reduces inflammatory cell infiltration; the traditional Chinese medicine composition assists the treatment of atopic dermatitis through the effects of the proinflammatory factors and the expression and secretion of the proinflammatory factors, has a remarkable treatment effect on the atopic dermatitis, is quick to take effect, small in toxic and side effects and good in safety, and has a good medicinal prospect.

The invention provides a nano-micelle responding to an inflammation microenvironment as well as a preparation method and application of the nano-micelle. According to the nano-micelle, polyethylene glycol (PEG)-poly L-glutamic acid (PLG) is grafted with 4-hydroxymethyl phenylboronic acid (PBA), and the drug loading capacity of a hydrophobic anti-inflammatory drug is improved based on a hydrophobic effect and a borate bond formed by the PBA and a 1, 3-diol or 1, 2-diol structure of dexamethasone, curcumin and luteolin. The nano-micelle (PPDex micelle) has reversible splitting and rapid release behaviors under an inflammatory condition (the ROS level is increased or the pH value is reduced). The nano-micelle has a proper particle size, can effectively relieve inflammatory cell infiltration and pulmonary edema in the lung of an acute lung injury (ALI) mouse after pulmonary administration, reduces pro-inflammatory cytokines in the lung, inhibits oxidative stress, promotes polarization of macrophages from pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, and finally inhibits the progress of ALI. The invention provides a novel effective anti-inflammatory strategy.

The present invention relates to a composition for preventing or treating gram-negative bacterial infections, the composition comprising T. ni cecropin. According to an aspect of the present invention, the peptide T. ni cecropin has the excellent effects of reducing liver and kidney toxicity values, inflammatory cytokine production, and endotoxins and inhibiting inflammatory cell infiltration in animal models infected with LPS-infected endotoxemia and Carbapenem-resistant Acinetobacter baumannii and can thus be effectively used for preventing or treating bacterial infections (e.g., gram-negative bacterial infections), sepsis, or inflammatory diseases.

The invention discloses a pharmaceutical composition for treating atopic dermatitis and a preparation method and application of the pharmaceutical composition for treating atopic dermatitis. The pharmaceutical composition comprises matrix vaseline, a humectant, a moistening agent, a repairing agent and an antioxidant. Two lipid components (gamma-linolenic acid and linoleic acid) are supplemented, so that eczema-like dermatitis can be obviously relieved, skin lesion inflammatory cell infiltration is reduced, the content of fatty acid in a skin barrier is recovered, treatment of atopic dermatitis is assisted, and the treatment effect on the atopic dermatitis is remarkable; the pharmaceutical composition disclosed by the invention has the advantages of quick effect on atopic dermatitis, small toxic and side effects, good safety and good medicinal prospect.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The invention relates to the technical field of medicines, in particular to medical application of a kedilao extract. The invention discloses the medical application of the kedilao extract for preventing, relieving and / or treating allergic asthma for the first time. The kedilao extract can reduce inflammatory cell infiltration, improve airway structure damage and improve airway wall thickening; the secretion of Th1 type cytokines is improved, the secretion of Th2 type cytokines is reduced, and the effect of obviously relieving asthma is achieved. Compared with an existing medicine for treating asthma, the kedilao extract is safer, more effective, milder and lasting, the action mechanism is multi-target and multi-effect, and the situation that a single-target medicine generates strong drug resistance is avoided. Therefore, the kdilao extract has considerable development and utilization values in the aspect of relieving and treating the allergic asthma.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention relates to the technical field of animal model construction, and discloses a non-alcoholic steatohepatitis model and a construction method and application thereof. The construction method comprises the following steps: performing stable overexpression on an AKT gene in the liver of a mouse by adopting a high-pressure caudal vein transfection technology, and feeding the mouse by adopting a high-fat feed. The non-alcoholic steatohepatitis model constructed by the construction method provided by the invention has the characteristics of liver inflammatory cell infiltration, liver fat deposition, insulin resistance, dyslipidemia and the like, has high clinical pathology similarity with NASH, has a remarkable steatohepatitis phenotype, can be used for researching the occurrence and development mechanism of NASH and evaluating the treatment effect of drugs, and has a wide application prospect. The method is of great significance to prevention and treatment of generation and development of NASH; meanwhile, the construction method is simple to operate, does not need transgenic animals, is short in feeding period, low in cost and high in efficiency, can effectively shorten the establishment period of the non-alcoholic steatohepatitis animal model, and has a good application prospect.

The invention relates to application of mogroside V in acetaminophen-induced liver injury, in particular to application of mogroside V in preparation of drugs for treating or preventing acetaminophen-induced liver injury. Research finds that mogroside V can obviously inhibit acetaminophen-induced liver injury, including reduction of liver necrosis area, reduction of serum glutamic-pyruvic transaminase and glutamic oxalacetic transaminase activity, and reduction of macrophage cell and inflammatory cell infiltration. Therefore, the ingestion of mogroside V is a medicine for effectively treating or preventing liver injury caused by excessive taking of acetaminophen.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

The invention discloses an intestinal microneedle anastomosis stent with an antibacterial function and a preparation method and application thereof, which can effectively and physically isolate an anastomotic stoma from intestinal contents and provide a relatively clean local environment for healing of the anastomotic stoma. The microneedle anastomotic stent is fixed at the anastomotic stoma, so that the tension at the anastomotic stoma can be further reduced, and the occurrence of anastomotic stoma leakage caused by overlarge tension is avoided; the microneedle layer on the surface of the stent can realize in-situ long-acting slow release of berberine hydrochloride (BBH) on the superficial layer of an anastomotic stoma, so that the drug utilization rate of the BBH is improved, the initial inflammation of the anastomotic stoma can be effectively reduced, and the anastomotic stoma can be regulated and controlled to be better healed. Animal experiment results prove that the implantation of the microneedle anastomosis stent can effectively reduce inflammatory cell infiltration of local tissues, reduce anastomotic stoma arrangement and regulate the anastomotic stoma to heal smoothly.